AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of the claims in the application.

(Previously Presented) A compound of general formula (1)

$$(R^2)_n$$
 $P-R^1$

wherein:

R¹, R² and R³ may be the same or-different and are independently hydrogen, substituted or unsubstituted alkynyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl,-C(O)-R⁸, --C(O)NR⁸R⁸, -S(O)_m-R⁸, -S(O)_m-NR⁸R⁸, nitro, -OH, cyano, amino, formyl, acetyl, halogen, -OR⁸, -SR⁸, or a protecting group and when two R² substitutents are ortho to each other, they may be joined to form a saturated or unsaturated cyclic ring, which may optionally include up to two heteroatoms selected from O. NR⁸ or S:

each occurrence of Rⁿ is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, or substituted or unsubstituted heterocyclylalkyl, or substituted or unsubstituted heterocyclylalkyl, or substituted or unsubstituted heterocyclylalkyl.

P is oxygen or sulfur;

n is an integer from 0 - 4;

Ar is substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heteroaryl ring;

X is oxygen or S(O)_m;

m is 0, 1 or 2;

Y is $-C(O)NR^4$:

R⁴ is hydrogen, substituted or unsubstituted alkyl, hydroxyl, -OR¹, -COOR¹, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic ring,

or an analog, tautomer, regioisomer, stereoisomer, enantiomer, diastereomer, pharmaceutically acceptable salt, N-oxide, or pharmaceutically acceptable solvate thereof.

2. (Previously Presented) A compound according to claim 1 wherein the substituents in the 'substituted alkyl', 'substituted alkoxy', 'substituted alkenyl', 'substituted alkynyl', 'substituted cycloalkyl', 'substituted cycloalkylalkyl', 'substituted cycloalkenyl', 'substituted arylalkyl', 'substituted aryl', 'substituted heterocyclic ring', 'substituted heteroaryl ring', 'substituted heteroarvlalkyl', 'substituted heterocyclylalkyl ring', 'substituted amino', 'substituted alkoxycarbonyl', 'substituted cyclic ring', 'substituted alkylcarbonyl', or 'substituted alkylcarbonyloxy' may be the same or different and are one or more of hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted guanidine, -COOR*, -C(O)R*, -C(S)R*, -C(O)NR*Ry, $-C(O)ONR^xR^y$, $-NR^xCONR^yR^z$, $-N(R^x)SOR^y$, $-N(R^x)SO_2R^y$, $=N-N(R^x)(R^y)$, $-NR^xC(O)OR^y$. $-NR^xR^y$. $-NR^{x}C(O)R^{y}$, $-NR^{x}C(S)R^{y}$, $-NR^{x}C(S)NR^{y}R^{z}$, $-SONR^{x}R^{y}$, $-SO_{2}NR^{x}R^{y}$, $-OR^{x}C(O)NR^{y}R^{z}$, $-OR^{x}C(O)NR^$ $OR^{x}C(O)OR^{y}$, $-OC(O)R^{x}$, $-OC(O)NR^{x}R^{y}$, $-R^{x}NR^{y}C(O)R^{z}$, $-R^{x}OR^{y}$, $-R^{x}C(O)OR^{y}$, $-R^{x}C(O)NR^{y}R^{z}$, $-R^{x}OR^{y}$, R^xC(O)R^x, -R^xOC(O)R^y, -SR^x, -SOR^x, -SO₂R^x, or -ONO₂, wherein R^x, R^y and R^z are independently hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroarylalkyl, or a substituted or unsubstituted heterocyclic ring.

- 3. (Original) The compound according to claim 1 wherein R¹ is substituted alkyl.
- (Original) The compound according to claim 3 wherein R¹ is CHF₂.
- 5. (Original) The compound according to claim 1 wherein R¹ is unsubstituted alkyl.
- (Original) The compound according to claim 5 wherein R¹ is methyl.
- 7. (Previously Presented) The compound according to claim 1 wherein P is S.
- 8. (Previously Presented) The compound according to claim 1 wherein P is O.
- (Previously Presented) The compound according to claim 1 wherein R² is substituted alkyl, halogen, eyano, nitro, amino, substituted heterocyclic ring or SO₂NR^aR^a and n=1.
- 10. (Original) The compound according to claim 9 wherein R² is chloro.
- 11. (Original) The compound according to claim 9 wherein R² is substituted alkyl.
- 12. (Original) The compound according to claim 11 wherein R² is CF₃.
- 13. (Original) The compound according to claim 9 wherein R² is -NH₂.
- 14. (Previously Presented) The compound according to claim 9 wherein R² is SO₂NR^aR^a.
- 15. (Original) The compound according to claim 14 wherein R² is SO₂N(CH₃)₂.

16. (Previously Presented) The compound according to claim 1 wherein Y is -C(O)NH-.

5

- 17. (Previously Presented) The compound according to claim 1 wherein Ar is substituted or unsubstituted 4-pyridyl; substituted or unsubstituted 4-pyridyl-N-oxide; substituted or unsubstituted 3-pyridyl-N-oxide; substituted or unsubstituted 2-pyridyl; or substituted or unsubstituted 2-pyridyl N-oxide.
- 18. (Previously Presented) The compound according to claim 17 wherein said Ar is substituted with halogen.
- 19. (Original) The compound according to claim 18 wherein said halogen is chloro.
- 20. (Previously Presented) The compound according to claim 17 wherein Ar is

21. (Original) The compound according to claim 20 wherein Ar is

22-62. (Canceled).

 (Previously Presented) A pharmaceutical composition comprising one or more compounds according to claim 1 and one or more pharmaceutically acceptable diluents or carriers.

64. (Canceled).

65. (Currently Amended) A method of treating an inflammatory condition or immune disorder selected from asthma, bronchial asthma, chronic obstructive pulmonary disease, allergic rhinitis, eosinophilic granuloma, nephritis, rheumatoid arthritis, cystic fibrosis, chronic bronchitis, multiple selerosis, Crohns disease, psoraisis, uticaria, adult vernal conjunctivitis, respiratory distress syndrome, rhematoid spondylitis, osteoarthritis, gouty arthritis, uveitis, allergic conjunctivitis, inflammatory bowel conditions, ulcerative colitis, eczema, atopic dermatitis and chronic inflammation in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound according to claim 1.

66-68. (Canceled)

69. (Currently Amended) The method according to claim 68 65 wherein said inflammatory condition is bronchial asthma, nephritis, or allergic rhinitis.

70-73. (Canceled)

74. (Previously Presented) A method for the preparation of a compound of general formula (1)

$$(R^2)_n$$
 R^3
 $P-R^1$

wherein:

R¹, R² and R³ may be the same or different and are independently hydrogen, substituted or unsubstituted alkvl, substituted or unsubstituted alkvnvl, substituted or unsubstituted alkvnvl.

substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heteroarylalkyl, -C(O)-R^a, -C(O)O-R^a, -C(O)NR^aR^a, -S(O)_m-R^a, -S(O)_m-NR^aR^a, nitro, -OH, cyano, amino, formyl, acetyl, halogen, -OR^a, -SR^a, or a protecting group and when two R² substitutents are ortho to each other, they may be joined to form a saturated or unsaturated cyclic ring, which may optionally include up to two heteroatoms selected from O, NR^a or S;

cach occurrence of R^a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclylalkyl, or substituted o

P is oxygen or sulfur;

n is an integer from 0-4;

Ar is substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring, or substituted or unsubstituted heteroaryl ring;

X is oxygen; or S(O)m;

m is 0, 1 or 2;

Y is $-C(O)NR^4$;

 R^4 is hydrogen, substituted or unsubstituted alkyl, hydroxyl, -OR¹, -COOR¹, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic ring,

or an N-oxide thereof;

comprising the steps of:

(a) reacting the compound of formula (11):

$$(R^2)_n$$
 X
 PR^1

with an amine of the formula ArNHR4 to yield a compound of formula (1)

$$(R^2)_n$$
 R^3 R^3 R^3 R^3 R^3

- (b) optionally converting the compound of formula (1) into its corresponding N-oxide.
- 75. (Currently Amended) The method of claim 74 wherein the compound of formula (11) is formed by
- (a) converting the compound of general formula (10)

$$(R^2)_n$$
 X
 PR^1
 R^3

to general formula (11) wherein FG represents substituted or unsubstituted alkyl, formyl, cyano, halogen, nitro, <u>or</u> amino or a carboxylic acid group.

- 76. (Previously Presented) The method of claim 75 wherein the compound of formula (10) is prepared by:
- (i) reacting a compound of formula (13.a) with a compound of formula (23) under basic conditions

wherein Z is a halogen; FG is a substituted or unsubstituted alkyl, formyl, cyano, halogen, nitro, or amino; and Hal is halogen, to yield a compound of formula (24)

- (ii) cyclizing the compound of general formula (24) under palladium catalyzed coupling conditions to form a tricyclic compound of general formula (10).
- 77. (Previously Presented) The method of claim 75 wherein the compound of formula (10) is prepared by:
- (i) reacting a compound of general formula (25) with an electrophile

wherein FG is alkyl, formyl, cyano, halogen, nitro, or amino; to yield a compound of formula (10).

- 78. (Currently Amended) The method of claim 75 wherein the compound of formula (10) is formed by:
- (i) reacting a compound of general formula (13) with a compound of formula (20) under basic conditions

10

20

to yield a compound of general formula (21)

wherein FG is alkyl, formyl, cyano, halogen, nitro, or amino; and Z is a halogen; and

(ii) cyclizing the compound of general formula (21) under acidic conditions followed by oxidation

to <u>yield yeild</u> a tricyclic compound of general formula (10).

79. (Previously Presented) The method of claim 75 wherein the compound of formula (10) is formed by:

(i) reacting a compound of formula (16) with a compound of formula (17)

where A is halogen, -OMs, -OTs or -B(OH)₂; Ms is a methanesulfonyl group; Ts is a p-toluenesulfonyl group; B₁ is halogen; G is a protecting group selected from benzyloxycarbonyl, t-butyloxycarbonyl, isopropyl, cyclopentyl, allyl, acetyl and benzyl[[,]]; FG is alkyl, formyl, cyano, halogen, nitro, or amino; and Z is halogen;

to yield a compound of formula (18)

$$(R^2)_n$$
 B_1
 GX
 FG
 R^3

(ii) deprotecting the compound of formula (18) to yield a compound of formula (19)

- (iii) cyclizing the intermediate of formula (19) under basic conditions to yield a tricyclic compound of formula (10).
- 80. (Previously Presented) The method of claim 75 wherein the compound of formula (10) is prepared by:
- (i) reacting a compound of general formula (12) where Z is a halogen

$$(R^2)_n$$
 Z
 Z

with an aromatic group of formula (13)

wherein FG is alkyl, formyl, cyano, halogen, nitro, or amino, under basic conditions to yield a compound of formula (14)

(ii) reducing the compound of formula (14) to obtain a compound of formula (15)

(iii) cyclizing the compound of formula (15) to yield a tricyclic compound of formula (10).

81. (Previously Presented) The method of claim 75, wherein (i) FG is methyl and step (a) comprises oxidizing the compound of formula (10) with a manganese or chromium reagent to form a compound of formula (11), (ii) FG is cyano and step (a) comprises hydrolyzing the compound of formula (10) to form a compound of formula (11), or (iii) FG is bromine and step (a) comprises reacting the compound of formula (10) with lithium followed by treatment with carbon dioxide to form a compound of formula (11).

12

- 82. (Previously Presented) The method of claim 74 wherein the compound of formula (11) is prepared by:
- (a) formylation of a compound of formula (26)

$$(R^2)_n$$
 X PR^1

followed by oxidation of the aldehyde group in the resulting compound of formula (27)

83-85. (Canceled).

86. (Previously Presented) A compound selected from

N-(3,5-dichloropyrid-4-yl)-4-methoxy dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-methoxy dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(3.5-dichloropyrid-4-vl)-4-methoxy-8-nitro dibenzo[b,d]furan-1-carboxamide.

N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-amino-dibenzo[b,d]furan-1-carboxamide, or a pharmaceutically acceptable salt thereof.

87. (Previously Presented) A compound selected from

N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide-N-oxide, or a pharmaceutically acceptable salt thereof.

88. (Previously Presented) A compound selected from

N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-nitro-dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-amino-dibenzo[b,d]furan-1-carboxamide, or a pharmaceutically acceptable salt thereof.

13

89. (Previously Presented) A compound selected from

N-(3,5-dichloropyrid-4-yl)-4-isopropyloxy dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-cyclopropylmethoxy dibenzo[b,d]furan-1-carboxamide

N-(3,5-dichloropyrid-4-yl)-4-benzyloxy dibenzo[b,d]furan-1-carboxamide, or

a pharmaceutically acceptable salt thereof.

90. (Previously Presented) A compound of claim 1 selected from

N-(pyrid-4-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(2-chloropyrid-3-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

N-(4-fluorophenyl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

 $N\hbox{-}(3,\,5\hbox{-}dichloropyrid\hbox{-}4\hbox{-}yl)\hbox{-}4\hbox{-}methoxy\hbox{-}8\hbox{-}trifluoromethyl\ dibenzo[b,d] furan-1\hbox{-}carboxamide,$

N-(3, 5-dichloropyrid-4-yl)-4-methoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide-N1-oxide.

N-(pyrid-4-yl)-4-methoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide-N1-oxide.

N-(pyrid-4-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-3-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide-N1-oxide,

 $N\hbox{-}(pyrid\hbox{-}2-yl)\hbox{-}4-difluoromethoxy-8-trifluoromethyl\ dibenzo[b,d] furan-1-carboxamide,$

 $N\hbox{-}(pyrid\hbox{-} 4\hbox{-} yl)\hbox{-} 4\hbox{-} difluoromethoxy\hbox{-} dibenzo [b,d] furan-1\hbox{-} carboxamide,$

N-(pyrid-3-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(5-chloropyrid-2-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide, or a pharmaceutically acceptable salt thereof.

91. (Previously Presented) A compound of claim 1 selected from

N-(3,5-dichloropyrid-4-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

14

N-(pyrid-4-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-3-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(3,5-dichloropyrid-4-yl)-4-hydroxycarbomethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-4-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-3-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-4-yl)-4-methoxy-8-nitro dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-8-nitro dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-chloro-dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-bromo-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-methoxy-8-bromo-dibenzo[b,d] furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-8-bromo-dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-iodo-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-methoxy-8-iodo-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-8-iodo-dibenzo[b,d]furan-1-carboxamide,

N-(4-methylpyrimid-2-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

 $N\hbox{-}(2,5\hbox{-}dichlor ophenyl)\hbox{-}4\hbox{-}methoxy\hbox{-}dibenzo[b,d] furan-l-carboxamide, or$

a pharmaceutically acceptable salt thereof.

- Docket No.: 04366/0200039-US0
- 92. (Previously Presented) A compound of claim 1 selected from
- N-(3,5-dichloropyrid-4-yl)-4-ethoxycarbomethoxy-dibenzo[b,d]furan-1-carboxamide,
- N-(3,5-dichloropyrid-4-yl)-4-methoxy-dibenzo[b,d]furan-2-carboxamide,
- N-(3,5-dichloropyrid-4-yl)-4-methoxy-dibenzo[b,d]furan-3-carboxamide,
- N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-cyano-dibenzo[b,d]furan-1-carboxamide,
- 3,5-Dichloro-4-(4-ethoxydibenzo[b,d]furan-1-ylcarboxamido)pyridine,
- N1-Benzyl-4-cyclopentyloxydibenzolb.dlfuran-1-carboxamide.
- 4-(4-Cyclopentyloxydibenzo[b,d]furan-1-ylcarboxamido)pyridine,
- 3,5-Dichloro-4-(4-cyclopentyloxydibenzo[b,d]furan-1-ylcarboxamido)pyridine,
- 4-(4-Methylsulfanyldibenzo[b,d]furan-1-ylcarboxamido)pyridine,
- 3,5-Dichloro-4-(4-ethoxydibenzo[b,d]furan-1-ylcarboxamido)pyridine-N-oxide,
- 3,5-Dichloro-4-(4-cyclopentyloxydibenzo[b,d]furan-1-ylcarboxamido)pyridine-N-oxide, or a pharmaceutically acceptable salt thereof.
- 93. (Canceled).
- 94. (Previously Presented) A compound of claim 1 selected from
- 3,5-Dichloro-4-(4-methoxydibenzo[b,d]-thiophen-1-ylcarboxamido)pyridine,
- 3,5-Dichloro-4-(4-cyclopentyloxydibenzo[b,d]-thiophen-1-ylcarboxamido)pyridine,
- N1-(4-methoxyphenyl)-4-methoxydibenzo[b,d]thiophene-1-carboxamide,
- N1-(4-methoxyphenyl)-4-methoxydibenzo[b,d]thiophene-1-carboxamide-5,5-dioxide,
- N1-(4-chlorophenyl)-4-methoxydibenzo[b,d]thiophene-1-carboxamide,
- 4-(4-methoxydibenzo[b,d]thiophene-1-ylcarboxamido)pyridine,
- 4-(4-Cyclopentyloxydibenzo[b,d]thiophene-1-yl-carboxamido)pyridine,
- 3,5-Dichloro-4-(4-cyclopentyloxydibenzo[b,d]-thiophen-5,5-dioxide-1-ylcarboxamido)pyridine-Noxide.
- 3,5-Dichloro-4-(4-methoxydibenzo[b,d]-thiophen-5,5-dioxide-1-yl-carboxamido) pyridine-N-oxide,
- $3,5- Dichloro-4-(4-methoxy dibenzo [b,d]-thiophen-5,5-dioxide-1-yl-carboxamido)\ pyridine,$
- 3,5-Dichloro-4-(4-difluoromethoxydibenzo[b,d]-thiophen-1-ylcarboxamido) pyridine,
- 2-(4-Methoxydibenzo[b,d]thiophen-1-ylcarboxamido)-pyridine,
- $\hbox{$4$-$(4-Ethoxy dibenzo[b,d]$ thio phen-1-yl-carboxamido)-pyridine,}\\$

- 3-(4-Methoxydibenzo[b,d]thiophen-1-ylcarboxamido)-pyridine,
- 3,5-Dichloro-4-(6-ethyl-4-methoxydibenzo[b,d]-thiophen-1-ylcarboxamido)pyridine,
- 3,5,dichloro-4-(4-ethoxy-dibenzo[b,d]thiophen-1-yl-carboxamido)pyridine,
- 3-(4-Methoxydibenzo[b,d]-thiophene-5,5-dioxide-1-ylcarboxamido)-pyridine,
- 3,5-Dichloro-4-(4-benzyloxydibenzo[b,d]-thiophen-1-ylcarboxamido)pyridine,
- N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-(pyrrolidine-2-one-1-yl)-dibenzo[b,d]furan-1-carboxamide, or

16

- a pharmaceutically acceptable salt thereof.
- 95. (Canceled).
- 96. (Previously Presented) N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-nitrodibenzo[b,d]furan-1-carboxamide or a pharmaceutically acceptable salt thereof.
- 97. (Previously Presented) N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-aminodibenzo[b,d]furan-1-carboxamide or a pharmaceutically acceptable salt thereof.
- (Previously Presented) A pharmaceutical composition comprising a compound of claim 96 and one or more pharmaceutically acceptable diluents or carriers.
- (Previously Presented) A pharmaceutical composition comprising a compound of claim 97 and one or more pharmaceutically acceptable diluents or carriers.